Focus: Eagle Pharmaceuticals is a public specialty pharmaceutical company focused on repurposing existing drugs, primarily generating revenue from its cancer franchise. The company operates with a highly concentrated revenue model centered on a single product.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Eagle Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Eagle Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eagle Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's sole meaningful revenue driver (100% of revenue); DNA cross-linking agent for cancer; exclusivity expires 2033.
Folate antagonist inhibitor in peak lifecycle; LOE protection extends to 2036, positioning as secondary revenue pillar post-BENDEKA LOE.
Alternate formulation/route of bendamustine; earlier LOE (2031) than BENDEKA suggests potential repositioning or life-cycle management product.
Generic ANDA product past exclusivity; minimal commercial value in portfolio.
Orphan-indication niche product with active pipeline expansion (heat stroke, exertional heat stroke Phase 2–3 programs) offering near-term clinical upside.
Eagle Pharmaceuticals stock (US2698191026): Filing on capital structure and outlook - AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): Filing on capital structure and outlook AD HOC NEWS
Elite Laboratories Inc, AbbVie Inc, Par Health USA LLC, Sunstar Americas Inc, eVenus Pharmaceutical Lab Inc, Navinta LLC, PTS Consulting LLC, Makro Technologies Inc, Eagle Pharmaceuticals Inc, CMC GMP LLC Withdraw Approval Of 16 Abbreviated Ne - marketscreener.com
Elite Laboratories Inc, AbbVie Inc, Par Health USA LLC, Sunstar Americas Inc, eVenus Pharmaceutical Lab Inc, Navinta LLC, PTS Consulting LLC, Makro Technologies Inc, Eagle Pharmaceuticals Inc, CMC GMP LLC Withdraw Approval Of 16 Abbreviated Ne marketscreener.com
Eagle Pharmaceuticals stock (US2698191026): focus shifts to pipeline and licensing after Bendeka set - AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): focus shifts to pipeline and licensing after Bendeka set AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): Court and cash runway remain key focus - AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): Court and cash runway remain key focus AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): Recent SEC filings highlight ongoing developments - AD HOC NEWS
Eagle Pharmaceuticals stock (US2698191026): Recent SEC filings highlight ongoing developments AD HOC NEWS
Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims - Law360
Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims Law360
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo